Novel Dual Notch/PXR Targeting for Colon Cancer Therapy

用于结肠癌治疗的新型双Notch/PXR靶向

基本信息

批准号：
8627820
负责人：
Shrikant Anant
金额：
$ 51.17万
依托单位：
UNIVERSITY OF KANSAS MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-01-01 至 2018-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8627820
关键词：
Adverse drug effect Affect Architecture Binding Binding Sites Biological Availability Biological Markers Calmodulin Cancer Etiology Cell Death Cell Maintenance Cells Cessation of life Clinical Research Clinical Trials Colon Carcinoma Data Development Dose Drug Industry Drug Kinetics Drug Targeting Drug resistance Drug toxicity Endothelial Cells Epithelial Cells Fibroblasts Fluorouracil Future Gene Activation Goals Growth HCT116 Cells In Vitro Lead Mediating Methods MicroRNAs Modeling Morbidity - disease rate Mus Neoplasm Metastasis Notch Signaling Pathway Oral Oral Administration Pathway interactions Pharmaceutical Preparations Pharmacodynamics Phosphorylation Phosphotransferases Proteins Receptor Activation Receptor Gene Regimen Research Role Signal Transduction Stem cells System Therapeutic Therapeutic Agents Toxic effect Trans-Activators Treatment Efficacy United States Water Woman Work Xenograft procedure analog base cancer cell cancer therapy cell type chemotherapeutic agent cis acting element in vivo intravenous administration killings men mortality mouse model new therapeutic target notch protein novel novel therapeutic intervention novel therapeutics pre-clinical preclinical safety preclinical study pregnane X receptor prevent promoter public health relevance receptor expression research study therapeutic target treatment strategy tumor tumor microenvironment tumor xenograft

项目摘要

SUMMARY Colon cancer remains a leading cause of cancer related morbidity and mortality, both in the US and around the world. Many therapeutic agents and their combinations are being used to inhibit the growth and metastasis of the tumor. However, a couple of significant problems with these strategies are the development of resistance to the drugs and the increased side effects of the drugs. A critical reason for the drug resistance is that directly or indirectly targeted therapeutics through various kinase pathways, they activate the pregnane X receptor (PXR). Hence, novel targeted therapeutics is essential that suppress specific pathways but do not induce PXR. In this regard, we have developed a novel drug MRLTHB and water-soluble analog MRLTHBCD, which inhibits Notch-1 signaling and does not induce PXR. The goal of the current project is to further characterize the drug and generate preclinical data as an oral therapeutic both alone and in combination with 5-fluorouracil (5-FU) for colon cancer. In previous studies, we have determined that downregulating Doublecortin calmodulin-like kinase 1 (DCLK1) suppresses colon cancer xenograft growth, suggesting that targeting DCLK1 would be an efficient strategy for colon cancers. We have now determined that THB and THBCD specifically inhibit DCLK1 kinase activity and but do not affect the kinase activity calmodulin like kinases CAMKII and CAMKIV. In addition, we have determined that the compounds inhibit the growth of colon cancer cells in a novel culture method that we have developed termed "Tumor in a Dish" (TiD) where cancer cells are grown in a three-dimensional culture that includes normal epithelial cells, fibroblasts and endothelial cells. The model creates an in vivo-like tumor microenvironment that provides the necessary cell-cell contact, 3D-architecture, and the influence of different cell types. The observed selective killing of cancer cells in this system suggests that the compounds are highly specific and have good potency. Mechanistically, we have determined that the compounds inhibit the Notch signaling pathway and PXR expression. Based on our preliminary studies, DCLK1 targeting by THB and THBCD resulting in suppression of both Notch signaling and PXR is a valid therapeutic strategy for colon cancers. We aim to continue developing preclinical data in the current application. In aim 1, we propose to determine the role of Notch-1 in PXR expression. In aim 2, we will perform detailed PK/PD studies of the compound and find the optimal dose to perform preclinical studies in xenotransplant and APCmin/+ mouse models. In aim 3, we propose then to continue and determine the effect of the combination of THB and THBCD with 5-fluorouracil to inhibit colon cancer growth. Effect of the compounds on Akt phosphorylation, Notch-1 activation, and DCLK1 and PXR expression in the tumor will be determined. These proposed studies would provide compelling mechanistic evidence for initiating clinical trials for the novel compounds alone and in combination. These studies will also aid in optimizing a targeted chemotherapeutic regimen and identify novel biomarkers for the future clinical studies.

概括在美国和周围，结肠癌仍然是癌症相关的发病率和死亡率的主要原因世界。许多治疗剂及其组合被用来抑制肿瘤。但是，这些策略的一些重大问题是抵抗的发展药物和药物的副作用增加。耐药性的关键原因是直接或通过各种激酶途径间接靶向治疗剂，它们激活妊娠X受体（PXR）。因此，新颖的靶向治疗剂是抑制特定途径但不会诱导PXR的必不可少的。在这方面，我们开发了一种新型的药物MRLTHB和水溶性类似物MRLTHBCD，它抑制了 Notch-1信号传导，不会诱导PXR。当前项目的目标是进一步描述该药物并与5-氟尿嘧啶（5-fu）一起生成临床前数据作为一种口服治疗结肠癌。在先前的研究中，我们已经确定下调双铁蛋白钙调蛋白样激酶 1（DCLK1）抑制结肠癌异种移植的生长，表明靶向DCLK1将是有效的结肠癌的策略。现在，我们已经确定THB和THBCD专门抑制DCLK1激酶活性，但不会影响激酶活性钙调蛋白，例如Camkii和Camkiv。另外，我们已经确定这些化合物在我们的新培养方法中抑制结肠癌细胞的生长已经开发出称为“菜肴中的肿瘤”（TID），其中癌细胞在三维培养物中生长其中包括正常的上皮细胞，成纤维细胞和内皮细胞。该模型创建一个体内样肿瘤提供必要的单元格接触，3D架构的微环境，以及不同的影响细胞类型。该系统中观察到的癌细胞的选择性杀死表明这些化合物高度高具体并且具有良好的效力。从机械上讲，我们已经确定化合物抑制了缺口信号通路和PXR表达。根据我们的初步研究，DCLK1针对THB和 THBCD导致抑制Notch信号和PXR是结肠的有效治疗策略癌症。我们的目标是继续在当前应用程序中开发临床前数据。在AIM 1中，我们建议确定Notch-1在PXR表达中的作用。在AIM 2中，我们将进行详细的PK/PD研究化合物并找到最佳剂量以在异种移植和Apcmin/+小鼠中进行临床前研究型号。在AIM 3中，我们建议继续并确定THB和THBCD的效果用5-氟尿嘧啶抑制结肠癌的生长。化合物对Akt磷酸化的影响Notch-1 将确定肿瘤中的激活，DCLK1和PXR表达。这些拟议的研究将提供令人信服的机械证据，用于单独和新型化合物启动临床试验组合。这些研究还将有助于优化靶向的化学治疗方案并确定新颖未来临床研究的生物标志物。